Study summary

A TROP2 antibody-drug conjugate beat chemotherapy after EGFR pills stopped working

OptiTROP-Lung04 trial (sac-TMT) · 376 people, phase 3 · Published January 2026, New England Journal of Medicine

8.3months without progression, vs 4.3 with chemotherapy

What was tested

Sacituzumab tirumotecan (sac-TMT), an antibody that delivers chemotherapy into cancer cells carrying TROP2, against pemetrexed and platinum chemotherapy after EGFR pills stopped working. Run in China.

What they found

What it means

Global trials (run by Merck) are testing whether the result holds outside China.

N Engl J Med, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.